방사성 요오드 저항성 갑상선암에서 수술적 치료의 역할

키워드

참고문헌 (77)

1. Schlumberger MJ, "Papillary and follicular thyroid carcinoma", N Engl J Med, 338, pp.297~306 (1998)
2. Hay ID, "2) Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989", Surgery, 114, pp.1050~1057 (1993)
3. Lin JD, "Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases", Thyroid, 9, pp.1227~1235 (1999)
4. Wartofsky L, "The use of radioactive iodine in patients with papillary and follicular thyroid cancer", J Clin Endocrinol Metab, 83, pp.4195~4203 (1998)
5. Schlumberger MJ, "Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status", J Endocrinol Invest, 22(11 Suppl), pp.3~7 (1999)
6. Robbins J, "Thyroid cancer: a lethal endocrineneoplasm", Ann Intern Med, 115, pp.133~147 (1991)
7. Gilliland FD, "Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991", Cancer, 79, pp.564~573 (1997)
8. Antonelli A, "Dedifferentiated thyroid cancer: a therapeutic challenge", Biomed Pharmacother, 62, pp.559~563 (2008)
9. Brenner H, "Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis", Lancet, 360, pp.1131~1135 (2002)
10. Schlumberger M, "Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma", J Clin Endocrinol Metab, 63, pp.960~967 (1986)
11. Pfister DG, "Treatment of Radioactive Iodine- Resistant Thyroid Cancer: Current Options and Future Directions. American Society of Clinical Oncology Educational Book, American Society of Clinical Oncology", VA Alexandria, pp.353~358 (2007)
12. Busaidy NL, "Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease", J Thyroid Res, 2012, pp.618985~ (2012)
13. Coburn M, "Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131)", Ann Surg, 219, pp.587~593 (1994)
14. Pacini F, "Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine", World J Surg, 18, pp.600~604 (1994)
15. Hoie J, "Distant metastases in papillary thyroid cancer. A review of 91 patients", Cancer, 61, pp.1~6 (1988)
16. Brown AP, "Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience", Br J Radiol, 57, pp.323~327 (1984)
17. Samaan NA, "Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients", J Clin Endocrinol Metab, 60, pp.376~380 (1985)
18. Massin JP, "Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment", Cancer, 53, pp.982~992 (1984)
19. Ruegemer JJ, "Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables", J Clin Endocrinol Metab, 67, pp.501~508 (1988)
20. Rossi RL, "Current results of conservative surgery for differentiated thyroid carcinoma", World J Surg, 10, pp.612~622 (1986)
21. Proye CA, "Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?", World J Surg, 16, pp.640~645 (1992)
22. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19, pp.1167~1214 (2009)
23. Stojadinovic A, "The role of operations for distantly metastatic well-differentiated thyroid carcinoma", Surgery, 131, pp.636~643 (2002)
24. Durante C, "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91, pp.2892~2899 (2006)
25. Rosenbluth BD, "Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer", Int J Radiat Oncol Biol Phys, 63, pp.1419~1426 (2005)
26. Haq M, "Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome", Clin Endocrinol (Oxf), 63, pp.87~93 (2005)
27. Lee J, "Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosisclinical outcomes and prognostic factors", Ann Surg, 251, pp.114~119 (2010)
28. Tickoo SK, "Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates", Arch Pathol Lab Med, 124, pp.1440~1447 (2000)
29. Orita Y, "Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma", Surgery, 147, pp.424~431 (2010)
30. Proye C, "Immunoscintigraphy or intraoperative isotopic detection of colorectal neoplastic lesions using labelled monoclonal antibodies. Preliminary study. 20 cases", Chirurgie, 115, pp.640~645 (1989)
31. 이잔디, "원격전이가 최초 증상으로 발현된 분화 갑상선암", 대한외과학회지, 71(2), pp.105~111 (2006), 대한외과학회
32. Schreinemakers JM, "Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management", World J Surg Oncol, 10, pp.192~ (2012)
33. -FDG-PET, "CT for Localizing Recurrence in Patients with Differentiated Thyroid Carcinoma", Journal of Korean Medical Science, 27(9), pp.1019~1026 (2012), 대한의학회
34. Tsang RW, "The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma", Cancer, 82, pp.375~388 (1998)
35. Farahati J, "Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4)", Cancer, 77, pp.172~180 (1996)
36. Schlumberger M, "Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma", J Nucl Med, 37, pp.598~605 (1996)
37. Schwartz DL, "Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment", Int J Radiat Oncol Biol Phys, 74, pp.1083~1091 (2009)
38. Droz JP, "Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy", Tumori, 76, pp.480~483 (1990)
39. Ahuja S, "Chemotherapy of thyroid carcinoma", J Endocrinol Invest, 10, pp.303~310 (1987)
40. Santini F, "Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer", J Clin Endocrinol Metab, 87, pp.4160~4165 (2002)
41. Haugen BR, "Management of the patient with progressive radioiodine non-responsive disease", Semin Surg Oncol, 16, pp.34~41 (1999)
42. Ouyang B, "Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET", PTC or BRAF mutations in vitro and in vivo, 2006, pp.12, 1785~1793
43. Belletti B, "Modulation of in vivo growth of thyroid tumorderived cell lines by sense and antisense vascular endothelial growth factor gene", Oncogene, 18, pp.4860~4869 (1999)
44. Bunone G, "Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features", Am J Pathol, 155, pp.1967~1976 (1999)
45. Klein M, "Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma", J Endocrinol, 161, pp.41~49 (1999)
46. Rosen LS, "Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors", J Clin Oncol, 25, pp.2369~2376 (2007)
47. Sherman SI, "Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer", N Engl J Med, 359, pp.31~42 (2008)
48. Schlumberger MJ, "Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer", J Clin Oncol, 27, pp.3794~3801 (2009)
49. Kloos RT, "Phase II trial of sorafenib in metastatic thyroid cancer", J Clin Oncol, 27, pp.1675~1684 (2009)
50. Gupta-Abramson V, "Phase II trial ofsorafenib in advanced thyroid cancer", J Clin Oncol, 26, pp.4714~4719 (2008)
51. Salgia R, "A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)", J Clin Oncol, 26(abstract), pp.3522~ (2008)
52. Mazzaferri EL, "Papillary and follicular thyroid cancer: a selective approach to diagnosis and treatment", Annu Rev Med, 32, pp.73~91 (1981)
53. Mazzaferri EL, "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer", Am J Med, 97, pp.418~428 (1994)
54. McGriff NJ, "Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer", Ann Med, 34, pp.554~564 (2002)
55. Pujol P, "Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer", J Clin Endocrinol Metab, 81, pp.4318~4323 (1996)
56. Mazzaferri EL, "Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer", J Clin Endocrinol Metab, 86, pp.1447~1463 (2001)
57. Kupferman ME, "Safety of modified radical neck dissection for differentiated thyroid carcinoma", Laryngoscope, 114, pp.403~406 (2004)
58. Uchino S, "Modified radical neck dissection for differentiated thyroid cancer: operative technique", World J Surg, 28, pp.1199~1203 (2004)
59. Robbins J, "Thyroid cancer: a lethal endocrine neoplasm", Ann Intern Med, 115, pp.133~147 (1991)
60. Ronga G, "Travascio L, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience", Q J Nucl Med Mol Imaging, 48, pp.12~19 (2004)
61. Do MY, "Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period", Endocr J, 52, pp.701~707 (2005)
62. Marcocci C, "Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma", Surgery, 106, pp.960~966 (1989)
63. Pittas AG, "Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients", Thyroid, 10, pp.261~268 (2000)
64. Qiu ZL, "Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer", J Clin Endocrinol Metab, 96, pp.3078~3086 (2011)
65. Quan GM, "Multidisciplinary treatment and survival of patients with vertebral metastases from thyroid carcinoma", Thyroid, 22, pp.125~130 (2012)
66. Sayama CM, "Cervical spine metastases: techniques for anterior reconstruction and stabilization", Neurosurg Rev, 35, pp.463~474 (2012)
67. Bernier MO, "Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas", J Clin Endocrinol Metab, 86, pp.1568~1573 (2001)
68. Demura S, "Total en bloc spondylectomy for spinal metastases in thyroid carcinoma", J Neurosurg Spine, 14, pp.172~176 (2011)
69. Ramadan S, "Spinal metastasis in thyroid cancer", Head Neck Oncol, 4, pp.39~ (2012)
70. Kushchayev S, "Percutaneous vertebroplasty for thyroid cancer metastases to the spine", Thyroid, 20, pp.555~560 (2010)
71. Patchell RA, "The treatment of brain metastases", Cancer Invest, 14, pp.169~177 (1996)
72. Patchell RA, "A randomized trial of surgery in the treatment of single metastases to the brain", N Engl J Med, 322, pp.494~500 (1990)
73. Noordijk EM, "The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age", Int J Radiat Oncol Biol Phys, 29, pp.711~717 (1994)
74. Nussbaum ES, "Brain metastases. Histology, multiplicity, surgery, and survival", Cancer, 78, pp.1781~1788 (1996)
75. Chiu AC, "Prognosis and treatment of brain metastases in thyroid carcinoma", J Clin Endocrinol Metab, 82, pp.3637~3642 (1997)
76. Sherman SI, "NCCN Thyroid Carcinoma Panel Members, NCCN practice guidelines in Oncology v1", 2009 Thyroid carcinoma, ~ (2009)
77. McWilliams RR, "Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years", Cancer, 98, pp.356~362 (2003)

관련 논문AI추천